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purpose of this study was to identify DDIs relevant for the ICU.Purpose: Drug-drug interactions (DDIs) may cause adverse outcomes in patients admitted to the Intensive Care
Materials and methods:We conducted a modiﬁed Delphi procedure with a Dutch multidisciplinary expert panel
consisting of intensivists and hospital pharmacists to assess the clinical relevance of DDIs for the ICU. The proce-
dure consisted of two rounds, each included a questionnaire followed by a live consensus meeting.
Results: In total the clinical relevance of 148 DDIs was assessed, of which agreement regarding the relevance
was reached for 139 DDIs (94%). Of these 139 DDIs, 53 (38%) were considered not clinically relevant for the
ICU setting.
Conclusions: A list of clinically relevant DDIs for the ICU setting was established on a national level. The clinical
value of CDSSs for medication safety could be improved by focusing on the identiﬁed clinically relevant DDIs,
thereby avoiding alert fatigue.
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Drug-drug interactions (DDIs) can lead to preventable adverse
clinical outcomes [1]. A DDI occurs when one or more drugs affect the
pharmacokinetics and/or pharmacodynamics of one or more other
drugs [2]. Patients in the Intensive Care Unit (ICU) are particularly sus-
ceptible for DDIs, due to often-present impaired absorption, diminished
renal and hepatic function, and polypharmacy [3]. In the ICU, DDIs cause
16% of all adverse drug events (ADEs), including both preventable and
non-preventable ADEs [4]. ADEs in the ICU are associated with higherkker),
f.keizer@amsterdamumc.nl
ersijs@erasmusmc.nl
nge), e.de_jonge@lumc.nl
nna),
. This is an open access article undermorbidity andmortality, prolonged length of stay, and increased hospi-
tal costs [5]. Computerized Decision Support Systems (CDSSs) that
show DDI alerts provide an opportunity to reduce risks related to
DDIs. Typically, DDI alerts warn prescribers about potential DDIs and
provide advice to change the medication regiment and/or plan neces-
sary additional monitoring. However, lack of a ﬁt between the general
knowledge base on which the DDI alerts are based and the clinical set-
ting may cause alert fatigue and high override rates [6–9].
In the ICU, up to 90% of the DDI alerts are overridden and around 84%
of these overrides are appropriate [10,11]. In contrast to other clinical
wards, ICU patients are under continuous monitoring which enables
timely detection and risk management of potential adverse effects of
DDIs. Furthermore, the critical condition of ICU patients may require
administration of interacting medications, despite the risk of adverse
effects. Therefore, some DDI alerts may be of no clinical value or even
unjustiﬁed in the ICU setting. A list of clinically relevant DDIs for the
ICU setting, agreed upon by ICU experts, may help tailoring DDI alert
content of CDSSs to the ICU setting. We hypothesize that such a listthe CC BY license (http://creativecommons.org/licenses/by/4.0/).
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(unintentionally) overriding relevant alerts, and thus improve medica-
tion safety.
Therefore, the objective of this study was to identify which DDIs are
considered clinically relevant for the ICU setting by conducting a modi-
ﬁed Delphi procedure with a national multidisciplinary expert panel
consisting of intensivists and hospital pharmacists.2. Materials and methods
This Delphi study is reported in accordance with the CREDES
reporting standard for Delphi studies [12] (Supplementary ﬁle 1). The
Delphi method is an often used method to obtain consensus from ex-
perts on medication related topics [13–15]. In a modiﬁed Delphi proce-
dure, the judgment and opinions from experts are collected using an
iterative process that involves a questionnaire and a live consensus
meeting [16]. Our modiﬁed Delphi procedure was based on the RAND
Appropriateness Method [17], a type of modiﬁed Delphi procedure,
and consisted of two rounds of a questionnaire and a live consensus
meeting (Fig. 1). During both rounds experts were asked to judge
each presented DDI on its clinical relevance for the ICU setting.
We did not ask our experts to make judgments about the severity
and evidence level of each DDI, since this information is already present
in the G-standard. This standard was originally developed for the pri-
mary care setting and nowadays serves as input for CDSSs in all Dutch
hospitals. A national committee assigns severity and evidence levels to
DDIs based on the Summary of Product Characteristics and review of lit-
erature [18]. This situation is unique, as in most countries the develop-
ment and maintenance of DDI knowledge bases are not organized at a
national level.
The DDIs were selected according to their severity level and fre-
quency in the ICU. For that purpose, we extracted retrospectivemedica-
tion administration data over a period of seven years from six Dutch
ICUs consisting of both small and large ICUs, situated in teaching and
non-teaching hospitals and geographically well spread over the
Netherlands.
After data-extraction, we screened the medication administration
data for the occurrence of DDIs using a computerized algorithm based
on the G-standard DDI knowledge base. For the ﬁrst Delphi round, we
selectedDDIs that occurred at least a hundred times. For the secondDel-
phi round, the remaining DDIs that have a severity level of D (severe
consequences reported), E (life threatening consequences reported) or
F (lethal consequences reported) were selected.Fig. 1. Timeline of our modi2.1. Expert panel
Experts were recruited from all fourteen Dutch ICUs participating in
the SIMPLIFY study [19] evaluating the effectiveness of decision support
on the number of DDIs in the ICU. All 14 ICUs were adult, closed format
mixed medical surgical ICUs. Together, these ICUs represent 311 beds
(mean: 22; SD: 13.2) and 23,452 yearly admissions (mean: 1675; SD:
1029). From each ICU, intensivists and hospital pharmacists were in-
vited to participate in the expert panel. In addition, two hospital phar-
macists and one clinical geriatrician were asked to participate because
of their expertise inmedication safety in ICU patients. In total 30 experts
were invited.
2.2. Questionnaire
For both Delphi rounds, we used an online questionnaire
(SurveyMonkey), presenting DDIs in subsections based on a similar
mechanism of action. To prevent bias due to the serial position effect
[20], we created two versions of both questionnaires by randomly
changing the order of the DDI subsections. Half of the experts were ran-
domized to receive one version; the other half received the other ver-
sion. The questionnaire was tested on one expert before distribution
to all experts. To support the experts during assessment, each DDI was
linked to its online risk analysis for background information. An exam-
ple of the questionnaire is available on request.
The questionnaire used in the ﬁrst round consisted of three
additional sections: respondent characteristics (twelve questions),
respondent's knowledge and opinion about DDI alerts on the ICU (six
questions), and feedback on the questionnaire (two questions). Experts
were invited via e-mail containing a link to the questionnaire. Experts
had one month to complete the questionnaire. When necessary,
e-mail reminders were sent.
2.3. Live consensus meeting
During both live consensus meetings, DDIs with a low agreement
score derived from the questionnaire were discussed. The purpose of
the meetings was to determine reasons for disagreement and see
whether the reasons represented genuine differences in opinion or dif-
ferences in interpretation. In the last case, agreement could still be
reached. A senior intensivist involved in the study (DD) chaired the
meetings. At the meeting, expert panel members received a paper ver-
sion of their questionnaire, to see how they had scored the DDIs. Each
DDI with a low agreement score was discussed for approximately ﬁveﬁed Delphi procedure.
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distribution of scores for the speciﬁc DDIwas shown. After discussion of
each DDI, the experts individually scored the DDI again. When these
scores would still result in a low agreement score, we accepted this re-
sult. After the consensus meeting, participants received a book token
and had the possibility to charge their travelling expenses.
2.4. Deﬁnitions of clinical relevance and agreement
For each DDI the experts were asked to score the clinical relevance
level of the DDIs for the ICU setting on a scale of 1 to 5 (Table 1).
A DDI is considered clinically relevant when themode score for clin-
ical relevance (the most often selected score) of the DDI is three or
higher, and the DDI does not have low agreement. A DDI is considered
not clinically relevant when the mode score is less than three, and the
DDI does not have low agreement. Based on the D7S method from
RAND [17], we deﬁned agreement as low when more than 10% of the
scores are a 1 or 2 andmore than 10% of the scores are a 5. DDIs with
low agreement were discussed during the live consensus meetings.
2.5. Outcomes
Our main outcome was the number and percentage of clinically rel-
evant DDIs and not clinically relevant DDIs.We categorized the number
and percentage of clinically relevant DDIs by type of increased risk re-
lated to the DDI. We also categorized by type of advised monitoring
strategy. Both categorizations are based on Uijtendaal et al. [21] and
information in the G-standard. Medication categories are based on the
Anatomical Therapeutic Chemical (ATC) Classiﬁcation System [22].
Differences between expert panel member characteristics in the ﬁrst
and second round were tested by a Chi squared or Fisher exact test
where appropriate. All analyses were performed with the R statistical
environment (3.4.1) [23].
3. Results
Screening the medication administration data of six Dutch ICUs for
DDIs resulted in a total occurrence of 216 unique DDIs. Of these, 73
DDIs occurred at least one hundred times and were selected for the
ﬁrst Delphi round. Seventy-ﬁve DDIs occurred less than one hundred
times but have a severity level of D, E or F were selected for the second
Delphi round. The remaining 68 DDIs were excluded (Fig. 2).
3.1. Round 1: frequently occurring DDIs
For theﬁrst questionnaire, 30 expertswere invited to participate and
assess the 73 frequently occurring DDIs. Twenty-seven experts
responded, resulting in a response rate of 27/30 (90%). Of these, 13
participated in the ﬁrst live consensus meeting. See Table 2 for expert
characteristics. No signiﬁcant differences were found between charac-
teristics of the experts participating in the ﬁrst questionnaire and the
experts participating in the ﬁrst live meeting.Table 1
Answer options to score the clinical relevance level of DDIs for the ICU setting.
Answer options to score the clinical relevance of DDIs for the ICU setting
1 Not clinical relevant, since adverse effects of this DDI are negligible.
2 Clinically relevant, the adverse effects of this DDI will however be limited since
routine monitoring to timely identify adverse effects is present.
3 Clinically relevant, the adverse effects of this DDI can however be limited by
additional monitoring and/or changes in dosage/frequency/timing.
4 Clinically relevant, the adverse effects of this DDI on the patient can be
substantial, however these effects are acceptable and treatable.
5 Clinically relevant, the adverse effect of this DDI on the patient should
preferably be avoided.Calculating the agreement scores of 73 DDIs assessed in the ﬁrst
questionnaire, seventeen (23%) DDIs scored low on agreement. These
seventeen DDIs were discussed during the ﬁrst live meeting and rated
again. Five DDIs remained with low agreement, while for twelve DDIs
agreement was reached. For 56 DDIs, agreement was already reached
based on the answers provided in the questionnaire. Overall, in the
ﬁrst round agreement was reached for a total of 68/73 (93%) DDIs. Of
these 68 DDIs, 25 (37%) were considered as clinically relevant for the
ICU, while 43 (63%) were considered as not clinically relevant. Fig. 2
shows a ﬂow diagram of the results of the ﬁrst and second round of
our Delphi procedure.
3.2. Round 2: less frequent but severe DDIs
For the second questionnaire, the same 30 experts were invited to
assess the remaining 75 DDIs. Twenty-six experts responded, resulting
in a response rate of 26/30 (87%). Of these, nine participated in the
second live consensus meeting. See Table 2 for expert characteristics.
No signiﬁcant differences were found between the characteristics of
the experts participating in the second questionnaire and the experts
participating in the second livemeeting. Furthermore, no signiﬁcant dif-
ferences were found between the experts participating in the ﬁrst and
second Delphi round.
In the second questionnaire, 24 (32%) DDIs scored low on agree-
ment. These 24 DDIs were discussed during the second live meeting
and rated again. Four DDIs remained with a low agreement score,
while for 20 DDIs agreement was reached. For 51 DDIs agreement was
reached based on the answers provided in the questionnaire. Overall,
in the second round, agreement was reached for a total of 71/75 (95%)
DDIs. Of these 71 DDIs, 61 (86%) were considered as clinically relevant
for the ICU, while 10 (14%) were considered as not clinically relevant
(Fig. 2).
Summarizing results from both Delphi rounds, agreement was
reached for a total of 139/148 (94%) DDIs. For a total of 9 DDIs (6%)
low agreement remained. Of these 139 agreed upon DDIs, 86 (62%)
were considered as clinically relevant for the ICU, while 53 (38%) were
considered as not clinically relevant. Supplementary ﬁle 2 provides a
full overview of all 148 DDIs and their mode scores.
In Table 3a, the proportion of clinically relevant DDIs per type of in-
creased risk is shown. All DDIs increasing the risk of hematologic distur-
bances were considered clinically relevant for the ICU setting, as well as
all DDIs with a risk of decreased efﬁcacy of immunomodulators, antibi-
otics, antimycotics, antipsychotics or anti-epileptics. Most DDIs poten-
tially causing cardiac arrhythmias or neurologic disturbances were
clinically relevant. On the other hand, none of the DDIs potentially caus-
ing electrolyte disturbances, masking hypoglycemia, or decreasing the
efﬁcacy of antithrombotics or lipid-modifying agents were clinically rel-
evant. In general, DDIs potentially inﬂuencing bloodpressure or increas-
ing the risk of bleeding were not clinically relevant.
Considering monitoring strategies (Table 3b), all DDIs for which
therapeutic drug monitoring or liver function monitoring is advised
were clinically relevant. In the category of risk-modifying strategies,
DDIs for which a time interval between administrations is advised
were mostly clinically relevant. At the same time, none of the DDIs for
which monitoring of glucose, potassium or sodium levels is advised
were clinically relevant. Furthermore, few of the DDIs for which blood
pressure or blood clotting time monitoring is advised were clinically
relevant.
4. Discussion
By conducting amodiﬁed Delphi procedure, for 148 DDIs the clinical
relevance in the ICU settingwas assessed by a nationalmultidisciplinary
expert panel. For 139 DDIs (94%) agreement on relevance was reached.
Overall, 53 of these 139 DDIs (38%) were assessed as not clinically rele-
vant. In the group of frequently occurring DDIs, 63% were assessed as
Fig. 2. Flowchart of both rounds of the modiﬁed Delphi procedure.
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vere DDIs, 14% of the DDIs was assessed as not clinically relevant.4.1. Strengths and limitations
This study has several strengths. First, to our knowledge this is the
only multicenter study that assessed the clinical relevance of DDIs for
the ICU setting through a Delphi procedure with a multidisciplinary ex-
pert panel. By using the Delphi method, opinions of experts can be col-
lected anonymously without a senior or powerful expert dominating
the outcome. The Delphi method is often used successfully to obtain
consensus from experts on medication related topics [16]. Also, discus-
sion in the live consensus meeting allowed the experts to reﬂect and
change opinions when necessary. Second, in both Delphi rounds the re-
sponse rates of the questionnaires were high. Third, selection of DDIs
was based on multicenter analysis of the DDI frequency on the ICU
and we combined this data with severity levels based on extensive
risk analyses.
This study also has limitations. First, the judgment of clinical rele-
vance of DDIs by experts is inherently subjective. Therefore, the results
of this study may not be agreed upon by all intensivists and hospital
pharmacists. However, this is inherent to each research area without a
gold standard. In a sensitivity analysis, we compared the assessment
of intensivists to the assessment of hospital pharmacists and we found
nodifferences. In addition, ICUs canhave different treatment population
and consequently prescribe different medication, resulting in possible
differences in clinical relevance of speciﬁc DDIs. Accordingly, the results
we found may not be an exact ﬁt for each ICU. However, the experts
who participated in our Delphi have considerable pharmacotherapy ex-
pertise and experience on the ICU and represent teaching and non-
teaching ICUs from fourteen different ICUs. Additionally, various patient
populations including cardio surgical, neurosurgical, transplant, trauma
and oncological patients are treated in these fourteen ICUs. Therefore
we are conﬁdent that the various types of ICU levels and appropriate ex-
pertise were sufﬁciently represented. In addition, we used a deﬁnition
for agreement of the clinical relevance level of a DDI based on the
established D7S deﬁnition of agreement from RAND [17].Second, our results are based on DDIs included in the Dutch
G-standard DDI knowledge base assessed by Dutch experts. Neverthe-
less, since frequently occurringDDIs in the ICU setting seemcomparable
between countries [24], our result could be generalizable to ICUs from
other countries. Furthermore, in our study we did not.
Assess all DDIs included in the DDI knowledge base of the
G-standard. However, we have identiﬁed characteristics of DDIs
(e.g. presence of routine monitoring to recognize potential adverse
effects) that could be used as a decision aid to assess whether or
not a DDI might be turned off in the ICU. This knowledge can be
used in the Netherlands but is also generalizable to ICUs in other
countries.
4.2. Comparison to literature
Our results are in line with ﬁndings from similar studies in which a
Delphi procedure was used to assess clinical relevance of DDIs
[25–27]. In the only study we found in the ICU setting by Askari et al.
[25], a single-center expert panel consisting of intensivists and pharma-
cists assessed the relevance of 53 severe DDIs that occurred in one ICU.
Compared to Askari et al., our study assessed more DDIs, both severe
and less severe, by a larger multicenter expert panel. Furthermore, our
selection of DDIs was based on a multicenter dataset as compared to a
single-center dataset used by Askari et al. Weingart et al. [26] assessed
clinical relevance of DDIs in the primary care setting. They found that
low and medium severe DDIs in general were not considered relevant
while severe DDIs were. Another study assessed the clinical relevance
of DDIs in the outpatient setting [27], they found that about half of the
DDIs were considered clinically relevant. As there are important differ-
ences between settings, such as differences in monitoring intensity be-
tween the ICU and other settings, it is important to determine clinical
relevance of DDIs for speciﬁc settings and using the obtained assess-
ment to improve clinical value of CDSSs.
4.3. Interpretation of our results
Comparing clinically relevant and clinically irrelevant DDIs, DDIs for
which nonstandardmonitoring, such as therapeutic drug monitoring, is
Table 2
Characteristics of expert panel members.
Characteristics Q1 (n = 27) CM1 (n = 13) Q2 (n = 26) CM2 (n = 9)
Gender, nmale (%) 20 (74.0) 9 (69.2) 19 (73.1) 6 (66.7)
Age in years, n (%)
31–40 3 (11.1) 2 (15.4) 3 (11.5) 2 (22.2)
41–50 9 (33.3) 4 (30.8) 11 (42.3) 5 (55.6)
51–60 15 (55.6) 7 (53.8) 12 (46.2) 2 (22.2)
Specialism, n (%)
Intensivist 17 (63.0) 7 (53.8) 14 (53.8) 4 (44.4)
Anesthesiology 6 (22.2) 3 (23.1) 5 (19.2) 2 (22.2)
Internist 9 (33.3) 3 (23.1) 7 (26.9) 2 (22.2)
Neurologist 1 (3.7) 0 (0.0) 1 (3.8) 0 (0.0)
Surgical 1 (3.7) 1 (7.0) 0 (0.0) 0 (0.0)
Clinical geriatrician 1 (3.7) 1 (7.0) 1 (3.8) 1 (11.1)
Hospital pharmacist 9 (33.3) 5 (38.5) 11 (42.3) 4 (44.4)
Clinical experience in years, n (%)
6–10 3 (11.1) 1 (7.0) 3 (11.5) 1 (11.1)
11–15 8 (29.6) 4 (30.8) 8 (30.8) 4 (44.4)
16–20 7 (25.9) 5 (38.5) 7 (26.9) 2 (22.2)
N21 9 (33.3) 3 (23.1) 8 (30.8) 2 (22.2)
Hospital type, n (%)
Academic 6 (22.2) 4 (30.8) 7 (26.9) 4 (44.4)
Teaching 14 (51.9) 7 (53.8) 12 (46.2) 3 (33.3)
General 7 (25.9) 2 (15.4) 7 (26.9) 2 (22.2)
Knowledge about DDIs, n (%)
Poor 1 (3.7) 1 (7.0) 1 (3.8) 0 (0.0)
Moderate 3 (11.1) 0 (0.0) 3 (11.5) 0 (0.0)
Good 14 (51.9) 8 (61.5) 14 (53.8) 6 (66.7)
Very good 6 (22.2) 1 (7.0) 5 (19.2) 1 (11.1)
Excellent 3 (11.1) 3 (23.1) 3 (11.5) 2 (22.2)
Knowledge about CDSSs, n (%)
Poor 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Moderate 3 (11.1) 2 (15.4) 2 (7.7) 0 (0.0)
Good 15 (55.6) 6 (46.2) 15 (57.7) 5 (55.6)
Very good 6 (22.2) 3 (23.1) 6 (23.1) 2 (22.2)
Excellent 3 (11.1) 2 (15.4) 3 (11.5) 2 (22.2)
Experience with CDSS alerts, n (%)
Yes 23 (85.2) 11 (84.6) 23 (88.5) 8 (88.9)
No 3 (11.1) 2 (15.4) 2 (7.7) 1 (11.1)
Other 1 (3.7) 0 (0.0) 1 (3.8) 0 (0.0)
Involvement CDSS own hospital/ICU, n (%)
Yes 15 (55.6) 9 (69.2) 13 (50.0) 6 (66.7)
No 12 (44.4) 4 (30.8) 13 (50.0) 3 (33.3)
Responsible for CDSS own hospital/ICU, n (%)
Yes 14 (51.9) 8 (61.5) 13 (50.0) 7 (77.8)
No 11 (40.7) 5 (38.5) 11 (42.3) 2 (22.2)
Other 2 (7.4) 0 (0.0) 2 (7.7) 0 (0.0)
Q1=Questionnaire 1, CM1=Consensusmeeting 1, Q2=Questionnaire 2, CM2=Consensusmeeting 2, ICU= Intensive CareUnit, DDI=Drug-Drug Interaction, CDSS=Computerized
Decision Support System.
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cally relevant according to ICU experts. Furthermore,most DDIs that de-
crease the efﬁcacy of medication therapy are considered clinically
relevant. Thismay be explained by the fact that success of ICU treatment
depends heavily on medication efﬁcacy. Finally, infrequent DDIs are
more often considered clinically relevant than frequent DDIs, probably
due to the unfamiliarity with the medication. It is important to realize
that frequently occurring DDIs produce most DDI alerts and therefore
have a larger share in the development of alert fatigue in comparison
to less frequent DDIs.
4.4. Implications and future research
Our ﬁndings can be used to tailor a DDI knowledge base used in
CDSSs in the ICU setting. Since the majority of the frequently occurring
DDIs are considered not clinically relevant, the number of DDI alerts
produced by a CDSS may be reduced substantially by turning off alerts
for these DDIs. By doing so, alert fatigue and high override rates may
markedly decrease, help focus on the relevant alerts and improve
patient safety.Besides using CDSSs, during the live consensus meetings experts
mentioned several other measures to reduce risks related to DDIs on
the ICU. For example, some ICU experts said to refrain fromusing certain
medication classes such as oral vitamin K antagonists and NSAIDs,
thereby preventing interactions that occur with these medication
classes.
Our results may encourage caregivers from other settings and de-
velopers of CDSSs, to establish a DDI knowledge base for a speciﬁc
setting of patient group such as children or frail elderly. Future re-
search is needed to examine whether tailoring DDI alerts based on
clinical relevance for the ICU results in improved effectiveness of
CDSS.
5. Conclusion
Using a modiﬁed Delphi procedure, we found that experts assessed
about 40% of the DDIs occurring in the ICU as not clinically relevant
for the ICU setting. This indicates that the clinical value of CDSSs for
medication safety could be improved by focusing on the identiﬁed clin-
ically relevant DDIs.
Table 3a
Clinical relevance of DDIs categorized by type of increased risk.
DDI group Proportion relevant DDIs(%)a
Increased risk of side effects/toxicity 47/86 (55%)
Masking hypoglycemia 0/3 (0%)
Electrolyte disturbance 0/8 (0%)
Cardiac arrhythmias (including QT
prolongation)
12/17 (71%)
Bleeding risk (including gastrointestinal ulcer
risk)
5/17 (29%)
Hypotension or hypertension 2/8 (25%)
Nephrotoxicity 3/4 (75%)
Myopathy 3/4 (75%)
Neurologic disturbances 19/24 (79%)
Hematologic disturbances 6/6 (100%)
Other 8/10 (80%)
Risk of decreased efﬁcacy 39/53 (74%)
Antihypertensive drugs 2/5 (40%)
Immunomodulators 2/2 (100%)
Benzodiazepines/opioids 2/4 (50%)
Antipsychotics (incl. haloperidol) 5/5 (100%)
Antibiotics 3/3 (100%)
Antimycotics 4/4 (100%)
Absorption (gastric protection) 6/6 (100%)
Antithrombotics 0/4 (0%)
Lipid-modifying agents 0/2 (0%)
Antiepileptics 8/8 (100%)
Other 6/9 (67%)
DDI = Drug-Drug Interaction.
a Numbersmay not add up to 139 and percentagesmay not add up to 100%, since DDIs
may fall in multiple categories.
Table 3b
Clinical relevance of DDIs categorized by type of monitoring strategy.
DDI group Proportion relevant DDIs(%)a
Monitoring of laboratory values 42/72 (58%)
Glucose 0/4 (0%)
Potassium 0/5 (0%)
Drugs (therapeutic drug monitoring) 37/37 (100%)
Blood clotting time (international normalized
ratio
2/16 (13%)
Kidney_function (serum creatinine 2/4 (50%)
Liver function 3/3 (100%)
Sodium 0/3 (0%)
Other 1/3 (33%)
Clinical monitoring 44/63 (70%)
ECG monitoring 7/9 (78%)
Blood pressure monitoring 1/7 (14%)
Avoid combination 46/66 (70%)
Adjust/titrate dose slowly 21/28 (75%)
Risk-modifying strategy 11/16 (69%)
Potassium or potassium-sparing diuretic 0/2 (0%)
Add gastric protection (proton pump inhibitor) 4/6 (67%)
Separate moments of oral administration 6/7 (86%)
Other 1/1 (100%)
Other 4/6 (67%)
DDI = Drug–Drug Interaction.
a Numbersmay not add up to 139 and percentagesmay not add up to 100%, since DDIs
may fall in multiple categories.
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